144 related articles for article (PubMed ID: 38780927)
1. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M; Rudra S; Bates JE; Remick JS; Joshi NP; Woody NM; Awan M; Geiger JL; Shreenivas A; Samsa J; Ward MC; Schmitt NC; Patel MR; Higgins KA; Teng Y; Steuer CE; Shin DM; Liu Y; Ahmed R; Koyfman SA
JAMA Oncol; 2024 May; ():. PubMed ID: 38780927
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial.
Gupta T; Sinha S; Ghosh-Laskar S; Budrukkar A; Mummudi N; Swain M; Phurailatpam R; Prabhash K; Agarwal JP
Radiat Oncol; 2020 Sep; 15(1):218. PubMed ID: 32938468
[TBL] [Abstract][Full Text] [Related]
3. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
4. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.
Ward MC; Riaz N; Caudell JJ; Dunlap NE; Isrow D; Zakem SJ; Dault J; Awan MJ; Vargo JA; Heron DE; Higgins KA; Beitler JJ; Marcrom S; Boggs DH; Hassanzadeh C; Reddy CA; Bonner JA; Yao M; Machtay M; Siddiqui F; Trotti AM; Lee NY; Koyfman SA;
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):586-594. PubMed ID: 28865925
[TBL] [Abstract][Full Text] [Related]
5. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial.
Rosenberg AJ; Agrawal N; Juloori A; Cursio J; Gooi Z; Blair E; Chin J; Ginat D; Pasternak-Wise O; Hasina R; Starus A; Jones FS; Izumchenko E; MacCracken E; Wolk R; Cipriani N; Lingen MW; Pearson AT; Seiwert TY; Haraf DJ; Vokes EE
JAMA Oncol; 2024 Jun; ():. PubMed ID: 38842838
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ; Ferris RL; Gillison M; Tahara M; Argiris A; Fayette J; Schenker M; Bratland Å; Walker JWT; Grell P; Even C; Chung CH; Redman R; Coutte A; Salas S; Grant C; de Azevedo S; Soulières D; Hansen AR; Wei L; Khan TA; Miller-Moslin K; Roberts M; Haddad R
JAMA Oncol; 2023 Jun; 9(6):779-789. PubMed ID: 37022706
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
10. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial.
Palma DA; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Eskander A; Higgins K; Karam I; Poon I; Husain Z; Enepekides D; Hier M; Sultanem K; Richardson K; Mlynarek A; Johnson-Obaseki S; Odell M; Bayley A; Dowthwaite S; Jackson JE; Dzienis M; O'Neil J; Chandarana S; Banerjee R; Hart R; Chung J; Tenenholtz T; Krishnan S; Le H; Yoo J; Mendez A; Winquist E; Kuruvilla S; Stewart P; Warner A; Mitchell S; Chen J; Parker C; Wehrli B; Kwan K; Theurer J; Sathya J; Hammond JA; Read N; Venkatesan V; MacNeil SD; Fung K; Nichols AC
JAMA Oncol; 2022 Jun; 8(6):1-7. PubMed ID: 35482348
[TBL] [Abstract][Full Text] [Related]
12. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.
Vargo JA; Ward MC; Caudell JJ; Riaz N; Dunlap NE; Isrow D; Zakem SJ; Dault J; Awan MJ; Higgins KA; Hassanadeh C; Beitler JJ; Reddy CA; Marcrom S; Boggs DH; Bonner JA; Yao M; Machtay M; Siddiqui F; Trotti AM; Lee NY; Koyfman SA; Ferris RL; Heron DE
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):595-605. PubMed ID: 28899556
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Lee A; Woods R; Mahfouz A; Kitpanit S; Cartano O; Mohamed N; Youssef I; Marqueen K; Sine K; Mah D; Neal B; Zakeri K; Kang JJ; Riaz N; Yu Y; McBride SM; Chen LD; Tsai CJ; Gelblum DY; Press RH; Michel LS; Sherman EJ; Pfister D; Dunn LA; Ho AL; Fetten J; Wong RJ; Boyle JO; Singh B; Cracchiolo JR; Ganly I; Cohen MA; Lee NY
JAMA Netw Open; 2023 Jan; 6(1):e2250607. PubMed ID: 36689229
[TBL] [Abstract][Full Text] [Related]
14. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
Gillison ML; Ferris RL; Harris J; Colevas AD; Mell LK; Kong C; Jordan RC; Moore KL; Truong MT; Kirsch C; Chakravarti A; Blakaj DM; Clump DA; Ohr JP; Deeken JF; Gensheimer MF; Saba NF; Dorth JA; Rosenthal DI; Leidner RS; Kimple RJ; Machtay M; Curran WJ; Torres-Saavedra P; Le QT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):847-860. PubMed ID: 36228746
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.
Lee NY; Harris J; Kim J; Garden A; Mechalakos J; Pfister DG; Chan ATC; Hu K; Colevas AD; Frank S; Shenouda G; Bar-Ad V; Waldron JN; Harari PM; Raben A; Torres-Saavedra P; Le QT
JAMA Netw Open; 2023 Jun; 6(6):e2316094. PubMed ID: 37266942
[TBL] [Abstract][Full Text] [Related]
16. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Leddon JL; Gulati S; Haque S; Allen C; Palackdharry S; Mathews M; Kurtzweil N; Riaz MK; Takiar V; Nagasaka M; Patil Y; Zender C; Tang A; Cervenka B; McGrath J; Korn WM; Hinrichs BH; Jandarov R; Harun N; Sukari A; Wise-Draper TM
Clin Cancer Res; 2022 Aug; 28(16):3464-3472. PubMed ID: 35653116
[TBL] [Abstract][Full Text] [Related]
19. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
20. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
